Previous 10 | Next 10 |
Amphastar currently has seven drugs under development, two drugs awaiting launch, and a base of over nine FDA-approved products in production. With the recent approval of generic ganirelix and vasopressin, which have a TAM of $850 million, AMPH could nearly double its revenue by YE 20...
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 1, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022, after the market closes on Monday, August 8, 2022, and will hold a conference call to discuss...
The U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals' ( NASDAQ: AMPH ) generic vasopressin injection. Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamine...
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Vasopressin injection, USP 20 Units/mL, 1mL Single Dose Vial...
Commercial-stage company, Amphastar Pharmaceuticals (NASDAQ:AMPH) dropped 22% on Thursday on the news that the FDA rejected its marketing application for AMP-015, a generic version of osteoporosis therapy teriparatide. In a presentation at the 2022 Jefferies Healthcare Conference Pr...
Gainers: Power bridge Technologies (PBTS) +177%. Applied UV (AUVI) +50%. Cardiff Oncology (CRDF) +38%. DBV Technologies (DBVT) +28%. View (VIEW) +24%. Viracta Therapeutics (VIRX) +22%. Finger Motion (FNGR) +21%. Scien joy (SJ) +20%. Aero Clean Technologies (AERC) +19%. Akso Health Group (AHG)...
The addiction treatment space has been pummeled along with everything else in the growth side of the stock market so far in 2022. For long-term investors, this could represent a huge gift, especially as some of the stocks in this space are also working in new domains and technologies, includi...
The addiction treatment space has been pummeled along with everything else in the growth side of the stock market so far in 2022. For long-term investors, this could represent a huge gift, especially as some of the stocks in this space are also working in new domains and technologies, includi...
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate Communications, will be presenting at the Jefferies Healthcare Conference on June 8, 2022 at 8:00 am E...
Generic drugmaker Amphastar Pharmaceuticals (NASDAQ:AMPH) announced on Monday that the FDA approved its Abbreviated New Drug Application ("ANDA") for Regadenoson, a bioequivalent and therapeutically equivalent to Lexiscan developed by Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY). Regadenoson i...
News, Short Squeeze, Breakout and More Instantly...
Amphastar Pharmaceuticals Inc. Company Name:
AMPH Stock Symbol:
NASDAQ Market:
Amphastar Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Complete Solaria Inc Com (CSLR) rose 58.5% to $1.775 on volume of 71,457,263 shares Senti Biosciences Inc. (SNTI) rose 55.1% to $0.428 on volume of 64,207,396 shares Golden Heaven Group Holdings Ltd. (GDHG) rose 13.3% to $0.1711 on vo...
2024-06-19 18:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...